Cure of Disseminated Human Lymphoma with [²²⁵Ac]Ac-Ofatumumab in a Preclinical Model

Abstract

Immunotherapies that target the CD20 protein expressed on most non-Hodgkin lymphoma cells have improved clinical outcomes, but relapse is common. We prepared ²²⁵Ac-labeled anti-CD20 ofatumumab and evaluated its in vitro characteristics and therapeutic efficacy in a murine model of disseminated human lymphoma. <b>Methods:</b>²²⁵Ac was chelated by DOTA-ofatumumab, and radiochemical yield, purity, immunoreactivity, stability, and chelate number were determined. In vitro cell killing of CD20-positive, human B-cell lymphoma Raji-Luc cells was assayed. Biodistribution was determined as percentage injected activity per gram (%IA/g) in mice with subcutaneous Raji-cell tumors (<i>n</i> = 4). [²²⁵Ac]Ac-ofatumumab biodistribution in C57BL/6N mice was performed to estimate projected human dosimetry. Therapeutic efficacy was tested in mice with systemically disseminated Raji-Luc cells, tracking survival, bioluminescence, and animal weight for a targeted 200 d, with single-dose therapy initiated 8, 12, or 16 d after cell injection, comparing no treatment, ofatumumab, and low (3.7 kBq/mouse) and high (9.25 kBq/mouse) doses of [²²⁵Ac]Ac- IgG and [²²⁵Ac]Ac-ofatumumab (<i>n</i> = 8–10/cohort). <b>Results:</b> Radiochemical yield and purity were 32% ± 9% and more than 95%, respectively. Specific activity wasmore than 5MBq/mg. Immunoreactivity was preserved, and more than 90% of the ²²⁵Ac remained chelated after 10 d in serum. Raji-Luc cell killing in vitro was significant, specific, and dose-dependent. In tumor-bearing mice, [²²⁵Ac]Ac-ofatumumab displayed low liver (7 %IA/g) and high tumor (28 %IA/g) uptake. Dosimetry estimates indicated that bone marrow is likely the dose-limiting organ.When therapy was initiated 8 d after cell injection, untreated mice and mice treated with cold ofatumumab or low- or high-dose [²²⁵Ac]Ac-IgG showed indistinguishable median survivals of 20–24 d, with extensive cancer-cell burden before death. Low- and high-dose [²²⁵Ac]Ac-ofatumumab profoundly (<i>P</i> &lt; 0.05) extended median survival to 190 d and more than 200 d (median not determinable), with 5 and 9 of 10 mice, respectively, surviving at study termination with no detectable cancer cells. Surviving mice treated with high-dose [²²⁵Ac]Ac-ofatumumab showed reduced weight gain versus naïve mice. When therapy was initiated 12 d, but not 16 d, after cell injection, high-dose [²²⁵Ac]Ac-ofatumumab significantly extended median survival to 40 d but was not curative. <b>Conclusion:</b> In an aggressive disseminated tumor model, [²²⁵Ac]Ac-ofatumumab was effective at cancer-cell killing and curative when administered 8 d after cell injection. [²²⁵Ac]Ac-ofatumumab has substantial potential for clinical translation as a next-generation therapeutic for treatment of patients with non-Hodgkin lymphoma.

Topics & Concepts